by Damon Race | Oct 10, 2023 | Press
October 10, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Europe Fall 2023, which will be held from November 14-15, 2023. GeneVentiv...
by Damon Race | Oct 2, 2023 | Press
October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...
by Damon Race | Sep 14, 2023 | Press
September 14, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company developing the first universal gene therapy for all types of hemophilia and the first for patients with inhibitors, today was announced...
by Damon Race | Aug 30, 2023 | Press
August 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present at BioPharm AmericaTM, which will be held in Raleigh,...
by Damon Race | Aug 29, 2023 | In the News
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Damon Race, CEO of GeneVentiv Therapeutics. The North Carolina-based startup hopes to develop a universal gene therapy that will benefit patients with hemophilia A or B with or without...
Recent Comments